Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares stood at 8.3 million during the latest session, with the company’s beta value hitting 2.61. At the last
In the last trading session, 1.36 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.60. With the company’s per
In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.78 million shares changing hands with its beta currently measuring 2.57. Company’s recent per share
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.60 and has seen 2.24 million shares traded in the last trading session. The ADAP
During the last session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 0.44 million, with the beta value of the company hitting 2.59. At the
In the last trading session, 2.42 million shares of the Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) were traded, and its beta was 2.60. Most recently the
In the last trading session, 0.35 million shares of the Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) were traded, and its beta was 2.60. Most recently the
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares stood at 1.74 million during the last session, with the company’s beta value hitting 2.50. At the close
In the last trading session, 2.4 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.51. With the company’s per
In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.49 million shares changing hands with its beta currently measuring 2.51. Company’s recent per share
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
